IsoRay (NYSEAMERICAN:ISR) has been assigned a $2.00 price objective by investment analysts at Maxim Group in a report issued on Thursday. The brokerage presently has a “buy” rating on the healthcare company’s stock. Maxim Group’s price target would suggest a potential upside of 354.55% from the stock’s current price.

IsoRay (ISR) opened at $0.44 on Thursday. The stock has a market capitalization of $25.35, a price-to-earnings ratio of -4.00 and a beta of 1.11. IsoRay has a 12-month low of $0.38 and a 12-month high of $0.69.

IsoRay (NYSEAMERICAN:ISR) last announced its earnings results on Thursday, February 8th. The healthcare company reported ($0.03) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.01). The company had revenue of $1.54 million for the quarter. IsoRay had a negative return on equity of 62.92% and a negative net margin of 127.66%.

In other IsoRay news, VP Michael Krachon purchased 55,000 shares of the firm’s stock in a transaction on Monday, November 20th. The stock was purchased at an average cost of $0.50 per share, for a total transaction of $27,500.00. Following the acquisition, the vice president now owns 19,609 shares in the company, valued at approximately $9,804.50. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Over the last quarter, insiders have acquired 92,440 shares of company stock valued at $44,292.

TRADEMARK VIOLATION WARNING: “IsoRay (ISR) Given a $2.00 Price Target by Maxim Group Analysts” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at

IsoRay Company Profile

IsoRay, Inc is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc, develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds.

Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with's FREE daily email newsletter.